0.9883
9.93%
0.0893
Precedente Chiudi:
$0.899
Aprire:
$0.899
Volume 24 ore:
39,754
Relative Volume:
1.01
Capitalizzazione di mercato:
$38.02M
Reddito:
$13.42M
Utile/perdita netta:
$-73.35M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-56.34M
1 W Prestazione:
-28.39%
1M Prestazione:
-25.89%
6M Prestazione:
-54.06%
1 anno Prestazione:
-63.67%
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
Nome
Barinthus Biotherapeutics Plc Adr
Settore
Industria
Telefono
44 (0) 1865 818808
Indirizzo
UNIT 6-10, ZEUS BUILDING, DIDCOT
Confronta BRNS con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
BRNS | 0.9883 | 38.02M | 13.42M | -73.35M | -56.34M | 0.00 |
VRTX | 448.94 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 746.62 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 597.27 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.44 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 108.05 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Barinthus Biotherapeutics Plc Adr Borsa (BRNS) Ultime notizie
New trial shows promise for chronic hepatitis B treatment - Investing.com India
Barinthus Bio completes enrollment for two clinical trials - Investing.com India
Barinthus Bio intiates Phase 1 clinical trial of VTP-1000 for treatment of coeliac disease - European Pharmaceutical Manufacturer
Barinthus Bio launches Phase 1 celiac disease therapy trial - Investing.com
Barinthus Biotherapeutics appoints new COO - Investing.com
BRNS Stock Touches 52-Week Low at $1.14 Amid Market Challenges - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket ... - Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket By ... - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Barinthus Bio refocuses on hepatitis B and celiac disease treatments By Investing.com - Investing.com
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections - GlobeNewswire Inc.
Market Update: Barinthus Biotherapeutics Plc. ADR (BRNS) Sees Negative Movement, Closing at 2.00 – DWinneX - The Dwinnex
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024 - Investing.com India
Kintara Therapeutics restructures share designations By Investing.com - Investing.com
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates - Zacks Investment Research
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
ANVS Stock Quote Price and Forecast - CNN
TPST Stock Quote Price and Forecast - CNN
Vaccitech (VACC) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Barinthus Biotherapeutics Plc Adr Azioni (BRNS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):